Substantiating this conjecture, we combined BD1047 and PD901 (hereafter PD901), a selective MEK inhibitor currently in clinical cancer trials which blocks MEK1 at values of 1 μmol/L in vitro 26. The gene discussed is MAP2K1; the disease is cancer.